Top 50 Life Science VC Funds & Investors in United States (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
ARCH Venture Partners
VC Fund
|
43 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $9.1M–$230M |
|
Alexandria Venture Investments
VC Fund
|
35 | United States, Canada, France | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$150M |
|
Alumni Ventures
VC Fund
|
27 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $850k–$75M |
|
Atlas Venture
VC Fund
|
25 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $750k–$115M |
|
8VC
VC Fund
|
24 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $2.5M–$181M |
|
Third Rock Ventures
VC Fund
|
22 | United States, Japan, Israel | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$190M |
|
OrbiMed
VC Fund
|
21 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $9.8M–$160M |
|
RA Capital Management
VC Fund
|
21 | United States, United Kingdom, China | Series B, Post-IPO Equity, Series A | Biotechnology, Health Care, Therapeutics | $20M–$275M |
|
SOSV
VC Fund
|
21 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Northpond Ventures
VC Fund
|
21 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $13M–$95M |
|
Gaingels
VC Fund
|
20 | United States, Canada, United Kingdom | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Health Care | $69k–$35M |
|
Google Ventures
VC Fund
|
20 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$121M |
|
Andreessen Horowitz
VC Fund
|
20 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $1.5M–$113M |
|
Liquid 2 Ventures
VC Fund
|
19 | United States, Mexico, Canada | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $125k–$48M |
|
Novartis Venture Fund
VC Fund
|
16 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
DCVC
VC Fund
|
16 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1M–$130M |
|
Felicis
VC Fund
|
15 | United States, Canada, United Kingdom | Series A, Seed, Series B | Software, Artificial Intelligence, SaaS | $1.5M–$75M |
|
Fifty Years
VC Fund
|
15 | United States, Germany, Canada | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $572k–$40M |
|
Foresite Capital
VC Fund
|
14 | United States, United Kingdom, China | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $17M–$270M |
|
Alix Ventures
VC Fund
|
14 | United States | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Life Science | $2M–$70M |
|
KdT Ventures
VC Fund
|
14 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
Flagship Pioneering
VC Fund
|
14 | United States, Canada, United Kingdom | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $6.6M–$230M |
|
Apple Tree Partners
VC Fund
|
14 | United States, Canada, United Kingdom | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.5M–$100M |
|
Lux Capital
VC Fund
|
14 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.6M–$150M |
|
Cormorant Asset Management
VC Fund
|
13 | United States, China, Switzerland | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $16M–$150M |
|
General Catalyst
VC Fund
|
13 | United States, India, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $1.6M–$123M |
|
Pear VC
VC Fund
|
13 | United States, Brazil, Colombia | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $250k–$40M |
|
TCA Venture Group
VC Fund
|
13 | United States, Canada, South Africa | Seed, Venture - Series Unknown, Convertible Note | Health Care, Software, Biotechnology | $50k–$8.5M |
|
The Column Group
VC Fund
|
13 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $15M–$120M |
|
Right Side Capital Management
VC Fund
|
12 | United States, Canada, United Kingdom | Pre-Seed, Seed, Convertible Note | Software, Artificial Intelligence, SaaS | $50k–$1.7M |
|
F-Prime
VC Fund
|
12 | United States, China, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $1.6M–$112M |
|
New Enterprise Associates
VC Fund
|
12 | United States, China, India | Series A, Series B, Series C | Software, Health Care, Biotechnology | $6M–$102M |
|
Khosla Ventures
VC Fund
|
12 | United States, United Kingdom, India | Series A, Seed, Series B | Artificial Intelligence, Software, Health Care | $1.8M–$100M |
|
MPM Capital
VC Fund
|
12 | United States, Canada, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$116M |
|
Civilization Ventures
VC Fund
|
12 | United States, United Kingdom, Brazil | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.8M–$144M |
|
Village Global
VC Fund
|
12 | United States, United Kingdom, India | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Financial Services | $250k–$22M |
|
Two Sigma Ventures
VC Fund
|
12 | United States, Canada, Mexico | Series A, Seed, Series B | Software, Artificial Intelligence, Machine Learning | $1.5M–$120M |
|
Omega Funds
VC Fund
|
12 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Hatteras Venture Partners
VC Fund
|
11 | United States, Canada | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $2.6M–$88M |
|
Sahsen Ventures
VC Fund
|
11 | United States, United Kingdom, China | Venture - Series Unknown, Seed | Biotechnology, Health Care, Non Profit | $1.2M–$135M |
|
Playground Global
VC Fund
|
11 | United States, Canada, Australia | Series A, Seed, Series B | Software, Artificial Intelligence, Robotics | $2.3M–$150M |
|
iSelect Fund
VC Fund
|
11 | United States, Canada, Australia | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Agriculture | $500k–$41M |
|
Connecticut Innovations
VC Fund
|
11 | United States, Israel, Canada | Seed, Series A, Series B | Health Care, Biotechnology, Software | $150k–$75M |
|
Digitalis Ventures
VC Fund
|
11 | United States, United Kingdom, China | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.5M–$132M |
|
SR One
VC Fund
|
11 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6M–$175M |
|
SV Angel
VC Fund
|
11 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1M–$100M |
|
Catalio Capital Management
VC Fund
|
11 | United States, Israel, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.7M–$208M |
|
Artis Ventures
VC Fund
|
11 | United States, United Kingdom, India | Series A, Series B, Seed | Health Care, Biotechnology, Software | $2.1M–$127M |
|
Longwood Fund
VC Fund
|
10 | United States, United Kingdom, Italy | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $16M–$141M |
|
TBD Angels
VC Fund
|
10 | United States, Kenya, Hong Kong | Seed, Pre-Seed, Angel | Software, Artificial Intelligence, Health Care | $54k–$16M |
| Access all 3567 VC funds in United States Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 472
- Round size: Series A $9.1M–$213M; Series B $15M–$230M; Series C $15M–$167M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $3B in 2024
Portfolio highlights
- Synchron — The endovascular brain computer interface.
- Ramona — At Ramona, we’re creating a high-throughput microscopy toolset to unlock a new perspective on cellular-level research. With a wider field of view and the capacity to capture data synchronously, we see more — and we see it in motion. By providing a new point of view, our technology enables researchers to make more informed decisions, faster.
- Moonwalk Biosciences — By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, France
Investor stats
- Total investments: 297
- Round size: Seed $2M–$30M; Series A $12M–$100M; Series B $25M–$150M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Leal Therapeutics — Leal Therapeutics develops novel therapeutics for patients.
- Vedana Therapeutics — Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2705
- Round size: Seed $850k–$9.9M; Series A $3.5M–$32M; Series B $8M–$75M
- Lead/follow: 4% lead, 96% follow
- Last fund: Likely actively investing — fresh fund, raised $90k in 2026
Portfolio highlights
- Particle — Afternic is a one-stop site to buy, sell and park domains. See for your self why Afternic is the world's premiere domain marketplace and exchange reseller.
- Akiba Digital — Akiba Digital is a data and technology company that provides financial intelligence solutions. Our vision is to to unlock financial opportunities for consumers, businesses and society using alternative data.
- Enact — Enact is a leading solar energy and solar software company serving homeowners, businesses, and installers. Get a free quote or request a demo today!
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 473
- Round size: Seed $750k–$25M; Series A $4M–$75M; Series B $8M–$115M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fresh fund, raised $400M in 2025
Portfolio highlights
- E Ink — E Ink Corp. is a supplier of electronic paper display (EPD) technologies. Products made with E Ink's electronic ink are designed to possess a paper-like high contrast appearance, ultra-low power consumption, and a thin, light form. E Ink's technology is tailored for many consumer and industrial applications including handheld devices,watches, clocks, and public information and promotional signs.
- Songbird — DropCatch.com helps you secure expiring domain names.
- Ethyreal Bio — Ethyreal Bio is an early-stage biotechnology company developing precision, mechanism-driven therapies for thyroid diseases with high unmet medical needs.
8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 670
- Round size: Seed $2.5M–$13M; Series A $7.7M–$55M; Series B $17M–$181M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $45M in 2026
Portfolio highlights
- Armadin Security — Armadin Security is an AI-powered cybersecurity company that specializes in real-time threat hunting.
- prime minute — Prime Minute develops disaster response technology and a platform for emergency operations and critical infrastructure resilience.
- Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Japan, Israel
Investor stats
- Total investments: 178
- Round size: Series A $19M–$110M; Series B $11M–$190M; Series C $20M–$108M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
- Jounce Therapeutics — Concentra is a biosciences company.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 762
- Round size: Series A $9.8M–$116M; Series B $23M–$148M; Series C $19M–$160M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fresh fund, raised $192M in 2026
Portfolio highlights
- CoGenesys — CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. The company develops peptide and protein-based medicines for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Bonovo Orthopedics —
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 578
- Round size: Series A $20M–$128M; Series B $27M–$151M; Post-IPO Equity $35M–$275M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $120M in 2025
Portfolio highlights
- Serapha Bio —
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 151
- Round size: Series A $13M–$65M; Series B $15M–$95M; Series C $23M–$85M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Faro AI — The AI Platform for Clinical Development
- Culture Biosciences — Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
- EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital todate. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1348
- Round size: Seed $1M–$8.1M; Series A $5M–$35M; Venture - Series Unknown $69k–$12M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $140k in 2026
Portfolio highlights
- MoneyStack — Financial stress can be an obstacle to mental health recovery. MoneyStack partners with healthcare teams to integrate financial counseling into treatment plans to improve mental health outcomes and support long-term recovery for individuals and families impacted by someone's behavioral health condition.
- Tiny Health — Tiny Health is the first at-home gut health test for moms and babies 0-3 years. Detect any gut imbalances early on and prevent chronic conditions.
- Charter Space — Charter is developing a collaborative platform for satellite mission logistics and program management available via web app and API that provides satellite operators with intuitive information architecture to streamline missions and reduce wasted engineering hours so they can get to the launchpad faster.Charter's platform usesdesign-focused UI/UX and automation to reduce friction through intuitive dashboarding, improved information sharing, and optimized compute and data resource efficiency. For satellite companies, ATLAS streamlines processes, automates manual tasks, and provides engineers with communications and information infrastructure to seamlessly interface both across teams and organisations. reduces wasted engineering hours and lead times, and minimizes upfront technical debt, CapEx, and long-run OpEx.In other words, Charter is building a logistics solution that will be to satellite logistics what the graphical user interface was to command-line interfaces.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1508
- Round size: Seed $1.1M–$16M; Series A $6M–$100M; Series B $15M–$121M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- ngmoco — ngmoco ("Next Generation MObile COmpany") is creating and producing games for the iPhone. CEO Neil Young is a former executive from Electronic Arts, where he oversaw the development of several hit titles. Another EA vet and partner at Kleiner Perkins, Bing Gordon, sits on the board. Kleiner is an investor through its iFund.
- SolveAI —
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2107
- Round size: Seed $1.5M–$16M; Series A $9M–$55M; Series B $17M–$113M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely actively investing — fresh fund, raised $1.2B in 2026
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- Phota Labs — Phota Labs is a developer of personalized AI photography tools preserving identity and memories.
- Supersonik — Supersonik provides an AI-powered platform for SaaS companies to offer 24/7 interactive product demos, enabling prospects to explore and personalize demos instantly without scheduling or manual intervention.
Liquid2 Ventures provides technology startups with seed-stage investments and is based in San Francisco, California. The firm was founded in 2015 by Joe Montana, Mike Miller, and Michael Ma.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Mexico, Canada
Investor stats
- Total investments: 1248
- Round size: Seed $1.1M–$9.1M; Pre-Seed $125k–$2.7M; Series A $6M–$48M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $12M in 2026
Portfolio highlights
- Albedo — Aerial quality imagery - from space.
- Complir — Complir's AI agents map product data, analyse compliance risks, generate documentation and track regulations across every market you sell in.
- Eden — Eden unifies medical imaging operations with clinical AI: PACS, teleradiology, AI-assisted diagnosis and structured reporting, deployed across 2,600+ imaging departments.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 234
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.
We are deep tech venture capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 514
- Round size: Seed $1M–$9.1M; Series A $6M–$42M; Series B $15M–$130M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely actively investing — fresh fund, raised $5M in 2026
Portfolio highlights
- Soteris — Soteris provides artificial intelligence-based pricing tools to the insurance business. The company is working hard to transform the entire insurance value chain and would like to keep you updated on developments.
- CH4 Global — CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change at scale. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced bycows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in Henderson, NV.
- Rainmaker Technology — Rainmaker uses drone-based cloud seeding to increase rainfall, restore ecosystems, and fight drought. Learn how our scalable weather technology brings water to the West.
Backing founders building iconic companies that transcend boundaries
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 707
- Round size: Seed $1.5M–$14M; Series A $4.4M–$42M; Series B $10M–$75M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fresh fund, raised $900M in 2025
Portfolio highlights
- Magentic — AI digital workers for the physical world
- Sooth Labs —
- Solcoa Industries — Solcoa Industries develops carbon-zero rare earth metals for critical supply chain needs and promote sustainable industrial practices
WE BACK HEROES using technology to solve the world's biggest problems
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 215
- Round size: Seed $2M–$13M; Pre-Seed $572k–$3.3M; Series A $8.5M–$40M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $90M in 2021
Portfolio highlights
- Onepot.ai — Synthesis is the bottleneck in discovery. We close it with AI and a wet lab built as one system. Our own data, our own models, chemistry radically faster.
- Wafer — Wafer is an AI optimization platform that automatically accelerates AI models by generating efficient custom GPU kernels.
- Adaption Labs — Adaptation creates AI systems that adjust to changing real-world circumstances.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 225
- Round size: Series A $17M–$165M; Series B $24M–$140M; Series C $37M–$270M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $900M in 2024
Portfolio highlights
- Thyme Care — Thyme Care is a dedicated team of nurses and care experts offering value-based cancer care to help you through all phases of the cancer experience.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Seed, Series A, Pre-Seed
- Geography: United States
Investor stats
- Total investments: 24
- Round size: Seed $2M–$12M; Pre-Seed $2.7M–$2.7M; Series A $12M–$70M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- iOrganBio — The Right Cells. Consistently. At Scale.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
- Italic Health — Italic Health, Inc. is a healthcare technology company building a unified platform for managing patient data, medical billing, and insurance workflows. Its software integrates health records, appointment scheduling, and AI-driven analytics to improve care coordination, financial processes, and patient engagement.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 96
- Round size: Seed $2.6M–$13M; Series A $9M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely actively investing — fresh fund, raised $4.9M in 2026
Portfolio highlights
- Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
- Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
- Tacit Therapeutics — Genetic medicines built on RNA trans-splicing. A new site is on the way.
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 256
- Round size: Series A $6.6M–$75M; Series B $11M–$230M; Series C $12M–$123M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $2.6B in 2024
Portfolio highlights
- ZoomInfo — ZoomInfo is the #1 GTM Platform: Marketing and sales AI plus the best B2B data. All-in-one lead generation, prospecting, market intelligence , and ABM software.
- Foghorn Therapeutics — Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter whatour DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
- Serif Biomedicines — Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies.
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 100
- Round size: Seed $3.5M–$8M; Series A $15M–$75M; Series B $29M–$100M
- Lead/follow: 63% lead, 37% follow
- Last fund: May invest from a new fund soon — raised $1B in 2020
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 702
- Round size: Seed $1.6M–$25M; Series A $7M–$90M; Series B $13M–$150M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fresh fund, raised $10M in 2026
Portfolio highlights
- Adimab — Premier Human Antibody Discovery and Optimization
- Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
- Enveda Biosciences — Enveda exists to give hope to millions of people around the world by accelerating the discovery of better medicines.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, China, Switzerland
Investor stats
- Total investments: 254
- Round size: Series A $16M–$102M; Series B $27M–$150M; Series C $30M–$146M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fresh fund, raised $75M in 2025
Portfolio highlights
- Epicrispr Biotechnologies — The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease.
- Processa Pharmaceuticals — Founded in Oct '17 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need.
- Cue Biopharma — A precision immuno-engineering company targeting transformative therapies for patients with significant unmet needs across allergic and autoimmune diseases.
Investing in powerful, positive change that endures
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 2288
- Round size: Seed $1.6M–$18M; Series A $6.7M–$75M; Series B $14M–$123M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely actively investing — fund raised in 2026
Portfolio highlights
- Datalogix — Datalogix® is the industry-recognized leader at connecting digital media and offline purchasing data. We help more than half of the top 100 consumer marketers increase the effectiveness and measurability of their advertising. DLX Platform®, encompasses over $1 trillion in consumer spending and powers campaigns for more than 75% of online mediacompanies. DLX ROI® is rapidly becoming the industry standard for measuring offline sales lift for digital media. Datalogix also offers predictive analytics for Direct Mail, and integrated media solutions via the DLX Net. Our expertise spans the major consumer segments, including Retail, CPG, Automotive, Telecom, Travel and Financial Services. We are based in Colorado, with offices in New York City, San Francisco, Boston, Chicago, Detroit, and London.
- Legora — By streamlining and simplifying legal workflows, we empower elite law firms and legal professionals to work more efficiently and effectively. Enabling them to focus on higher-value tasks and deliver exceptional results for their clients.
- Ayr Energy — Ayr Energy designs, engineers, manufactures, and supplies power transformers, distribution transformers, switchgear, and circuit breakers.
Pear VC partners with entrepreneurs from day zero to build category-defining companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Brazil, Colombia
Investor stats
- Total investments: 525
- Round size: Seed $1.6M–$9M; Pre-Seed $250k–$3.5M; Series A $8.5M–$40M
- Lead/follow: 19% lead, 81% follow
- Last fund: Likely still investing — raised $3.4M in 2024
Portfolio highlights
- Forus — From PA generation to appeals, enrollments, & pharmacy navigation, Forus handles the end-to-end medication access process. Forus supports every drug, insurance, and pharmacy to help patients get access to life-changing medications.
- Piston — Payments technology company for the logistics Industry
- Hertha Metals — At Hertha Metals, we are developing advanced steel solutions to accelerate the growth and global competitiveness of the U.S. steel industry.
TCA Venture Group is the largest angel investor group in the United States, possessing more than 300 members in five networks in Los Angeles, Orange County, San Diego, Central Coast, and the Inland Empire. Its members provide funding and guidance to more early-stage, high-growth companies in Southern California than any other investment group.Members invest in companies in a wide range of industries, including the life sciences, biotech, IT, services, retail, Internet, financial, software, media, consumer products, and tech startups. TCA as a whole gives companies more than just capital; they also provide counsel, mentoring, and access to an extensive network of potential investors, customers, strategic partners, and management talent. Tech Coast Angels has been ranked by CB Insights to be among the Top 20 Angel Groups in the US; TCA was also ranked as #1 for Network Centrality, meaning we have more connections than anyone! If you are in the game-changing business, we are here to help.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Seed, Venture - Series Unknown, Convertible Note
- Geography: United States, Canada, South Africa
Investor stats
- Total investments: 393
- Round size: Seed $525k–$3.8M; Convertible Note $50k–$4.5M; Venture - Series Unknown $400k–$8.5M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- EdgeX — Edokonta builds software that allows hospitals to track mobile equipment, such as IV pumps and ultrasounds. The company was founded in 2018 and based in San Diego, California.
- Nested Knowledge — Nested Knowledge is designing an interface that allows you to examine the data from a comprehensive literature review on research questions of interest. The interactive, nested features facilitate therapeutic comparisons, assist with research organization, and allow physicians to compare nuances across patient characteristics and outcomes.
- Major Medical Devices — Major Medical Devices develops next-generation vascular devices for endovascular repair and related surgical procedures.
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 163
- Round size: Series A $15M–$102M; Series B $22M–$120M; Series C $37M–$120M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Nura Bio — Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders.
- InduPro — InduPro is a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies.
- Circle Pharma — Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
Systematic Pre-Seed Startup Capital
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Pre-Seed, Seed, Convertible Note
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 2067
- Round size: Seed $50k–$1.7M; Pre-Seed $50k–$450k; Convertible Note $50k–$400k
- Lead/follow: 3% lead, 97% follow
- Last fund: Likely actively investing — fresh fund, raised $55M in 2025
Portfolio highlights
- tbh — tbh is a developer of a mobile application designed to provide anonymous feedback to friends. The company's mobile application facilitates asking or answering questions, open text fields and invite abuse when combined with anonymity, enabling users to say things without repercussions and feel better about themselves from the positive feedbackon social networks.
- Vidrovr — Vidrovr develops multimodal computer vision and machine learning systems to index, tag, and understand video. It processes videos with specific domain constraints, such as in sports, government, and media verticals. Its technology enables its users to search an indexed video corpus and retrieve content inside videos and link it to other media likephotos and text.The company Integrates social media to enable direct interactions between multimedia content. Vidrovr was founded in 2016 and is headquartered in New York.
- TasksMind — Customer Reliability Platform
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 542
- Round size: Seed $1.6M–$20M; Series A $8M–$87M; Series B $15M–$112M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Innovent Biologics — Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. Theregistered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
- Mersana Therapeutics — Discover how Day One is disrupting the status quo of traditional drug development to bring new medicines to children and adults with cancer.
- PlasmaGen Biosciences — PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy.Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need.They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, China, India
Investor stats
- Total investments: 2087
- Round size: Series A $6M–$55M; Series B $10M–$85M; Series C $15M–$102M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $468M in 2024
Portfolio highlights
- Zyngenia —
- ARRIS — High-volume producer of advanced carbon parts for drones, aerospace, cycling, and consumer applications. (Made in U.S.A. or Taiwan)
- Lithium Technologies — Lithium builds trusted relationships between the world’s best brands and their customers, helping people get answers and share their experiences. Brands like Microsoft, HP, Sephora, Virgin and Barclaycard and customers in more than 34 countries rely on Lithium to help them connect, engage, and understand their total community. With more than 100million monthly visits over all Lithium communities and 750 million online profiles scored by Klout, Lithium has one of the largest digital footprints in the world. Using that data and the company’s software, Lithium customers boost sales, reduce service costs, spark innovation, and build long-term brand loyalty and advocacy.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 1495
- Round size: Seed $1.8M–$22M; Series A $5.5M–$47M; Series B $10M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2026
Portfolio highlights
- C the Signs — Discover C the Signs: a cutting-edge cancer prediction system enhancing early detection and survival. Committed to reducing healthcare disparities.
- LanzaTech — LanzaTech is turning our global carbon crisis into a feedstock opportunity with the potential to displace 30% of crude oil use today and reduce global CO2 emissions by 10%. By recycling carbon from industrial off-gases; syngas generated from any biomass resource (e.g. municipal solid waste (MSW), organic industrial waste, agricultural waste); andreformed biogas, LanzaTech can reduce emissions and make new products for a circular carbon economy.LanzaTech’s carbon recycling technology is like retrofitting a brewery onto an emission source like a steel mill or a landfill site, but instead of using sugars and yeast to make beer, pollution is converted by bacteria to fuels and chemicals! Imagine a day when your plane is powered by recycled GHG emissions, when your yoga pants started life as pollution from a steel mill. This future is possible using LanzaTech technology.
- littleBits Electronics — LittleBits is an open source library of over 60 electronic modules that snap together with magnets allows users to view, download, and share designs and make their own Bits through the use of prototypes. Deluxe kit, Smart home kit, Arduino coding kit, Synth kit, hardware development kit, and workshop set are some of the electronics learning modulesprovided by littleBits.LittleBits was launched by Ayah Bdeir in 2011 and is operated from New York, United States.
Powering Breakthroughs in Life Sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 241
- Round size: Series A $10M–$80M; Series B $20M–$116M; Series C $12M–$109M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $850M in 2021
Portfolio highlights
- Orna Therapeutics — Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
- Aratana Therapeutics — Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. We are committed to bringing world class science to animal health for companion animals and the people who care for them. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercialproducts for companion animals in a cost effective and efficient manner.
- Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 76
- Round size: Seed $1.8M–$16M; Series A $8.1M–$30M; Series B $24M–$144M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $35M in 2020
Portfolio highlights
- OxCan — Enabling curative cancer treatment through early detection
- 10x Science — AI-native software to unlock drug development.
- Rinascera Therapeutics — Rinascera Therapeutics develops transformative therapies for rare genetic skin diseases, including RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic Epidermolysis Bullosa (DEB).
Early stage venture capital backed by some of the world's best entrepreneurs.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Financial Services
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 514
- Round size: Seed $1.5M–$10M; Pre-Seed $250k–$3.5M; Series A $7M–$22M
- Lead/follow: 20% lead, 80% follow
- Last fund: May invest from a new fund soon — raised $125M in 2021
Portfolio highlights
- microagi — Accelerating embodied AGI
- Legato Audio — Legato Hearing develops stylish glasses with built-in hearing technology, offering a discreet alternative to traditional hearing aids.
- Cast Insights — Cast Insights is an AI-powered platform that turns global spoken content—TV, radio, podcasts, livestreams—into structured, searchable real-time intelligence for investors, policy teams, strategists, and newsrooms.
We are an early-stage venture capital firm investing in transformative companies harnessing information growth and computing power to change the world.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Mexico
Investor stats
- Total investments: 275
- Round size: Seed $1.5M–$8M; Series A $7.5M–$70M; Series B $15M–$120M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $400M in 2022
Portfolio highlights
- Swarm Aero — Swarm empowers small teams to mobilize thousands of uncrewed vehicles in communications-limited, contested environments.
- Artemis — Artemis is the first protective layer that is AI-native
- littleBits Electronics — LittleBits is an open source library of over 60 electronic modules that snap together with magnets allows users to view, download, and share designs and make their own Bits through the use of prototypes. Deluxe kit, Smart home kit, Arduino coding kit, Synth kit, hardware development kit, and workshop set are some of the electronics learning modulesprovided by littleBits.LittleBits was launched by Ayah Bdeir in 2011 and is operated from New York, United States.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $470M in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Canada
Investor stats
- Total investments: 142
- Round size: Series A $2.6M–$50M; Series B $5M–$82M; Series C $8M–$88M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $30M in 2023
Portfolio highlights
- RapidPulse — Explore RapidPulse for innovative stroke treatments and technologies. Book appointments or learn about our team and clinical trials.
- 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
- Ladder Health — Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy.
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Non Profit
- Stage:Venture - Series Unknown, Seed
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 101
- Round size: Seed $1.2M–$25M; Venture - Series Unknown $1.5M–$135M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Synthesize Bio — Deep biomedical data is the key to unlocking discoveries and creating therapies. Synthesize Bio uses AI to reduce data collection and analysis from months to minutes for a fraction of the cost in time, personnel, and materials.
- Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
- ZymeCO — ZymeCO is a bio-manufacturing company that develops enzyme-based biological products designed for sustainable agriculture and turf management. The company utilizes a bio-process that transforms organic matter to build soil health, accelerate residue decomposition, and boost plant growth.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Playground Global is an early-stage venture capital firm backing technical and scientific founders with deep engineering expertise, a collaborative environment, and a first-hand understanding of the intricacies of deep tech. Established in 2015 and headquartered in Palo Alto, CA, Playground’s mission is to transform ambitious ideas into impactfulbusinesses that benefit humanity and the planet. We invest in areas that span across next gen compute automation, energy transition and engineered biology. Playground has been an early – and frequently first investor – in companies that include PsiQuantum, Relativity Space, Ultima Genomics, MosaicML (acq. by Databricks), d-Matrix, and Strand Therapeutics.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Robotics
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 155
- Round size: Seed $2.3M–$14M; Series A $8M–$44M; Series B $20M–$150M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fresh fund, raised $475M in 2026
Portfolio highlights
- RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
- Mesa Quantum — Mesa Quantum develops chip-scale quantum sensing technology including atomic clocks and inertial sensors for position, navigation, and timing as a GPS alternative.
- Delos Data — Delos Data develops AI-focused interconnect hardware and network analytics software for large-scale artificial intelligence workloads.
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more...Investment focus
- Industry: Biotechnology, Health Care, Agriculture
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 117
- Round size: Seed $500k–$9M; Series A $600k–$41M; Venture - Series Unknown $1.2M–$24M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $3.8M in 2019
Portfolio highlights
- Miraterra — A New Era of Measurement: Unlocking the Secrets of Soil, Plants, and Food. Our breakthrough technology, overcoming decades of limitations, provides fast, efficient and trustworthy digital measurements when and where you need them most.
- Mercy BioAnalytics — We are making early-stage cancer easier to find using extracellular vesicles found in blood, specific to their parent cells.
- Vive Crop Protection — Vive Crop Protection makes effective and sustainable pesticides for organic and non-organic production. The company creates new ways to use proven crop protection products using their targeted Allosperse Delivery System, which improves the targeting and performance of pesticide active ingredients. This helps farmers do more with less, all whileincreasing crop quality and yields.Vive Crop Protection was founded in 2006 and is headquartered in Mississauga, Ontario, Canada.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 309
- Round size: Seed $150k–$5.3M; Series A $1.8M–$25M; Series B $1.8M–$75M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $50M in 2023
Portfolio highlights
- CloudSEK — CloudSEK leverages contextual AI to predict and prevent cyber threats. Keep your organisation safe and secure.
- NovaTract Surgical — NovaTract Surgical is a development stage company, intends to develop medical devices to address the rapidly growing field of Single Incision Laparoscopic Surgery (SILS) and Natural Orifice Transluminal Endoscopic Surgery (NOTES). The company was incorporated in 2010 and is based in Guilford, Connecticut.
- Axerion Therapeutics — Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury.Axerion was established in New Haven to develop and commercialize intellectual propertylicensed from Dr. Stephen Strittmatter’s laboratory at Yale University. Axerion’s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.
Engineering solutions to complex problems in health through venture investment and company creation.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 118
- Round size: Seed $1.5M–$15M; Series A $7.5M–$66M; Series B $13M–$132M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $300M in 2023
Portfolio highlights
- Omni — Omni provides Healthy Vegan Dog Food in the UK, made by vets to be a nutritionally complete meal for your dog. Feed your dog all the goodness of plants backed by science.
- Buddy Bites — Subscription pet food delivered straight to your door! Convenient & healthy pet food approved by vets. Made in Europe with premium quality. 2kg to you, 1kg donated to Hong Kong pet shelters.
- Sparkle Grooming Co. — Sparkle is a national wellness-focused dog grooming franchise and pioneer of Quick Service Pet Care (QSPC), a modern approach to routine pet care that combines membership-based services, technology-enabled operations, and a premium salon experience. The company provides recurring grooming and wellness services designed to keep dogs clean, healthy,and happy while helping franchise partners build scalable pet care businesses across the country.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 202
- Round size: Series A $6M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $237M in 2025
Portfolio highlights
- CalciMedica — CalciMedica is a clinical-stage biopharmaceutical company advancing CRAC channel inhibitors for pulmonary hypertension and acute pancreatitis.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
SV Angel is a service organization, investing in founders who share these values. They support entrepreneurs in building lasting companies by assisting at key inflection points and leveraging networks to help them propel their businesses forward.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1394
- Round size: Seed $1M–$11M; Series A $3M–$35M; Series B $8.3M–$100M
- Lead/follow: 2% lead, 98% follow
- Last fund: Likely actively investing — fresh fund, raised $430M in 2025
Portfolio highlights
- Hyperpublic — Hyperpublic is an open database of people, places, and things tied to a specific location. Anyone can add objects to the database and developers will be able to build applications on top of the data.
- Flow Engineering — Flow Engineering develops AI-powered systems engineering software for requirements management, validation, and hardware design workflows.
- Proximal — Proximal builds AI training data and environments to improve software engineering agents and autonomous coding systems.
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, Switzerland
Investor stats
- Total investments: 148
- Round size: Series A $9.7M–$150M; Series B $26M–$130M; Series C $70M–$208M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $16M in 2026
Portfolio highlights
- Evvy — Evvy is a developer of at-home vaginal microbiome tests to close the gender health gap and improve female health. It uses metagenomic sequencing to understand symptoms and risks for critical health challenges, and get personalized reports.
- Avava — Avava is a Pioneer precision skin therapy to improve the quality of life for patients around the world.
- OSPRI — OSPRI is updating the infectious illness testing plan. Established by the combination of Community Direct DX, Scienetix, and the R&D section of Advanta Genetics, OSPRI is among the first molecular testing platforms in the world to be entirely vertically integrated.
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 151
- Round size: Seed $2.1M–$35M; Series A $5M–$57M; Series B $20M–$127M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $141M in 2023
Portfolio highlights
- GenHealth.ai — GenHealth.ai provides healthcare solutions using generative AI trained on encoded medical events. Its product is a generative healthcare AI publicly available. It includes a foundation transformer model (new neural networks with excellent memory), an API, and user applications that can generate and predict future sequences of health events usinghistorical events. Together they can be used to build a large variety of customized applications.
- Ozlo Sleep — Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.
- Stateless Networks — Performance, Visibility. Simplicity...It's time for a beautiful network. Stateless is transforming network operations for software-centric networking. Tying together deep network understanding with state-of-the-art distributed systems, cloud, data science and gaming expertise, Stateless transforms network visibility, performance andresponse and helps accelerate the transition to modern network platforms, tying together physical and virtual layers. Focused on the enterprise data center, Stateless currently partners with the world’s leading network and infrastructure vendors (including VMware (VMW), Cisco Systems (CSCO), Cumulus Networks and others) to deliver solutions to some of the world’s largest private data center operators. We’re looking for software and networking engineers in Greater Seattle and the Bay Area with expertise in one or more of the following areas: Distributed Systems, Service Oriented Architecture, Complex Event processing, Functional Programming, Virtualization, Network design and deployment, Network programming, Network troubleshooting, configuration and performance tuning and SDN. Bonus points for experience working with cloud infrastructure (AWS, Azure, OpenStack) or low-level systems software (linux kernel, hypervisors, compilers/language runtimes), complex gaming systems or graphics and computational geometry. For more information visit http://www.statelessnetworks.com/ or follow Stateless on Twitter: @statelessntwrks.see
Investing where Discovery becomes Patient Care As life science venture investors, industry connectors, and company founders, Longwood Fund identifies and
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Italy
Investor stats
- Total investments: 81
- Round size: Series A $16M–$100M; Series B $30M–$141M; Series C $17M–$100M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $158M in 2023
Portfolio highlights
- Neomorph — We engineer neomorphic protein surfaces to unlock targeted protein degradation.
- Coultreon Biopharma — Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune disease. Our pipeline targets SIK3 to deliver transformative therapies where unmet need remains high.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
TBD Angels is a group of like-minded angel investors who thrive on sharing advice, guidance, and capital with talented entrepreneurs. TBD Angels provide critical advice and connections to jumpstart the companies it invests in.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, Kenya, Hong Kong
Investor stats
- Total investments: 96
- Round size: Seed $334k–$6M; Angel $54k–$3M; Pre-Seed $200k–$16M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Penny Finance — Get a tailored financial & investing plans, track your money making, learn about personal finances & get new insights, all in the Penny Finance investing app for women.
- Yuva Biosciences — Using cutting edge mitochondrial science to develop cosmeceuticals and pharmaceuticals.
- Cayuga Biotech — Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayugais developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.
Life Science VC funding in United States at a glance
Stats across 4k deals from 3.6k investors.
Access all 3567 VC funds in United States Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in United States investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 3567 VC funds investing in United States Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!